Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“A drug with "potential for abuse" short of "high" but no "accepted" medical use does not fit into any of the CSA schedules.”
UnverifiableConfidence: LOW

Reasoning

The evidence from Reason.com cites the statutory criteria for CSA schedules and notes the gap for substances that have some abuse potential but lack accepted medical use, confirming the claim.

On confidence: The provided excerpts explicitly state that a drug with abuse potential less than 'high' and no accepted medical use does not fit into any CSA schedule.

Important context

CSA schedules are defined by three criteria: potential for abuse, accepted medical use, and safety under medical supervision. The gap arises because schedules only differentiate 'high' versus lower abuse potential, leaving no category for lower abuse potential without medical use.

Evidence

Supporting (2)

Limitations

The evidence is limited to a single secondary source summarizing the statutory language; no primary legal text is provided, but the summary aligns with known CSA definitions. No independent origin corroborated this claim, so it cannot be verified and confidence cannot be high.

Last verified:
Oct 1, 2026, 4:49 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Hazy Drug Classification Criteria Invite Dubious Bureaucratic Judgments

Reason · Jacob Sullum